This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer

List of authors.
  • Clara Montagut, M.D., Ph.D.,
  • and Joana Vidal, M.D.

Liquid biopsy, the detection of tumor-related DNA in the peripheral blood, is currently the best available technological tool to improve clinical decision making in precision oncology.1 Liquid biopsy currently has enough analytic and clinical validity to be implemented in routine practice for advanced disease genotyping to predict the benefit of targeted drugs. An additional great promise of the measurement of circulating tumor DNA (ctDNA) has been its use for the detection of the so-called minimal residual disease, particularly after surgical therapy to remove primary tumors, as a predictor of residual disease and relapse and as an indicator of poor prognosis.2,3 . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.

This editorial was published on June 4, 2022, at NEJM.org.

Author Affiliations

From the Department of Medical Oncology, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques, Centro de Investigación Biomédica en Red Cáncer, Barcelona.